Prescription Medicines
Rotrovan Tab. 10mg
- Product Category
- Hyperlipidemia treatment
- Active Ingredients
- Rosuvastatin Calcium
- Appearance
- Pink round film-coated tablets
- Reimbursement Code
- 648103340
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Rosuvastatin calcium (EP) ---------- 10.4mg (10mg as rosuvastatin)
- Additives (tar color aluminum lake): Red No. 40, Yellow No. 5
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry pink (03B44038), calcium hydrogen phosphate hydrate, carnaubanap, copovidone, crospovidone
2. Efficacy/Effectiveness
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb): When not controlled through diet and exercise
dietary supplements
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia
4. Pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia who still meet the criteria below despite diet therapy
As an adjunct to diet to reduce total cholesterol, LDL-cholesterol, and apo-B protein levels in patients (for women, at least 1 year after menarche)
◦ If LDL-cholesterol is still greater than 190 mg/dL (LDL-C > 190 mg/dL)
◦ LDL-cholesterol still exceeds 160 mg/dL (LDL-C > 160 mg/dL), family history of premature cardiovascular disease, or two or more cardiovascular diseases
If you have risk factors
5. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
6. Reduced risk of cardiovascular disease: There is no clinical evidence for coronary heart disease, but high-sensitivity C-reactive protein is present in men over 50 years of age and women over 60 years of age.
(high sensitive C-reactive protein, hsCRP) is greater than 2 mg/L, and at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level,
in patients with risk factors such as smoking or a family history of premature coronary heart disease)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Usage/Dosage
1. Primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and
Homozygous familial hypercholesterolemia:
Patients before and while taking this drug should eat a standard cholesterol-lowering diet, and this should be continued during the treatment period. Take this medicine at any time of the day, regardless of meals.
Medication can be administered. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. Maintenance dose: once a day
At 10 milligrams, most patients are controlled at this dose. The maintenance dose is administered at intervals of 4 weeks or more depending on LDL-cholesterol levels, treatment goals, and patient response.
It must be adjusted appropriately, and the dose can be increased up to 20 milligrams per day.
2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age):
The usual dosage range is 5 milligrams to 20 milligrams once daily. (There is no clinical data on doses higher than 20 milligrams administered in the pediatric patient group.) The administered dose varies depending on the individual patient.
Adjust individually according to recommended treatment goals. The dosage should be adjusted at intervals of 4 weeks or more. Safety and efficacy for children under 10 years of age have been established.
There is not.
3. Elderly: No dosage adjustment is necessary.
4. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. 20 mg of this drug for patients with moderate renal failure
Particular care must be taken when administering.
5. Patients with liver failure: In patients with a Child-Pugh score of 7 or less, no increase in systemic exposure of rosuvastatin was observed, but in patients with a Child-Pugh score of 8 or 9, there was no increase in systemic exposure of rosuvastatin.
increased. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. In patients with active liver disease
Do not administer this drug.
6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
7. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. For some of these patients, administration of a 40-milligram dose of this drug may be
It's taboo.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the components of this drug
2) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
3) Patients with myopathy
4) Patients taking cyclosporine concurrently
5) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
6) Pregnant and lactating women, and women of childbearing potential who do not use appropriate contraceptive methods.
This drug should be administered to women of childbearing age only when there is a high possibility that they will not become pregnant and when they have been informed of the potential risk to the fetus.
7) Administration of this drug at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal damage (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Like other HMG-CoA reductase inhibitors, this drug should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting treatment with this drug. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before taking this drug.
2) As with other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as unexplained myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving this drug. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including this drug. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with kidney damage
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
․ During treatment, you should immediately report any unexplained muscle pain, weakness, or cramps, especially if they are associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting this drug or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
․ Because it may make interpretation of the measurement results difficult, do not measure CK after intense exercise or when there are other causes that may increase CK values. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
3) Administration of this drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
4) Statin drugs can rarely cause or worsen severe muscle atony or ocular muscle atony, and cases of recurrence have been reported when the same or different types of statin drugs were administered. This drug should be used with caution in patients with these conditions, and treatment should be discontinued if severe muscle or ocular muscle atony is induced or worsens.
5) In clinical trials, there was no evidence of increased effect on skeletal muscle in the small number of patients who received this drug in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyrosporin, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams is contraindicated when administered concomitantly with fibrate-based drugs.
6) In patients taking high doses, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving 40 mg.
7) Pharmacokinetic tests showed that systemic exposure increased (median AUC and Cmax increased approximately 2-fold) in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
8) Pediatric patients aged 10 - 17 years: In pediatric patients taking rosuvastatin, evaluation of secondary sexual characteristics, linear growth (height), weight, and BMI (body mass index) by Tanner staging is limited to one year.
9) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
*Table: Refer to manual
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered this drug, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) with or without acute renal failure have been reported in patients treated with all doses of this drug (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving this drug. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Eye disorders: Ocular muscle atony (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with eosinophilia and systemic symptoms (DRESS), lichenoid drug rash (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks).
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, adverse drug reactions for which a causal relationship with this drug cannot be ruled out were 2.92% (90 people, 106 cases).
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
7) Pediatric patients aged 10 to 17 years
In a 52-week clinical trial conducted on pediatric patients aged 10 to 17 years, elevated creatinine kinase levels exceeding 10 times the upper limit of normal range (10 x ULN) after exercise and increased physical activity were observed more frequently than in adult patients. In other respects, the safety profile of pediatric patients was similar to that of adults.
4. General precautions
1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including this drug. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
3) An increase in HbA1c and fasting blood sugar levels was reported when administering HMG-CoA reductase inhibitors, including this drug.
4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
5) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
6) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), increased eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
5. Interaction
1) How other drugs affect this drug
In vitro and in vivo studies have shown that this drug does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
This drug is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. If this drug is used together with an inhibitor of this transporter protein, the blood concentration of this drug may increase, increasing the risk of myopathy (see table below).
*Table: Refer to manual
The following drugs did not have a clinically significant effect on the AUC ratio of rosuvastatin when administered in combination with rosuvastatin.
- Aleglitazar 0.3 mg for 7 days; Fenofibrate 67 mg 3 times daily for 7 days; Fluconazole 200mg once daily for 11 days; fosamprenavir 700 mg/ritonavir 100 mg twice daily for 8 days; Ketoconazole 200 mg twice daily for 7 days; Rifampin 450 mg once daily for 7 days; Silymarin 140mg 3 times a day for 5 days
Effects of other drugs
- Antacids: As a result of co-administration of this drug with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by approximately 50%. However, this effect was alleviated when antacids were administered 2 hours after administration of this drug. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
- Ticagrelor: Ticagrelor has been shown to increase rosuvastatin concentrations and may increase the risk of myopathies, including rhabdomyolysis. When coadministered, the benefit of preventing major cardiovascular events associated with rosuvastatin use and the risk of increased rosuvastatin plasma concentrations should be considered. When 90 mg of ticagrelor was administered and 10 mg of rosuvastatin was administered 1 hour later, the Cmax and AUC of rosuvastatin increased by about 2.6 times.
2) How this drug affects other drugs
- Warfarin: When used in combination with this drug, warfarin has no significant effect on pharmacokinetics. However, as with other HMG-CoA reductase inhibitors, co-administration of this drug and warfarin may increase the INR compared to administration of warfarin alone. In patients receiving vitamin K antagonists (e.g. warfarin), INR monitoring is recommended when starting, discontinuing, or adjusting the dose of this drug.
- Cyclosporine: Co-administration of this drug and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMG-CoA reductase inhibitors. When co-administered with fibrate drugs, administration of 40 mg of this drug is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data on patients taking this drug and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
6. Administration to pregnant and lactating women
The safety of this drug in pregnant and lactating women has not been established, so it should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using this medicine, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. Limited data have been reported on the transfer of this drug into breast milk in humans, and there is a potential risk of adverse effects in infants due to its mechanism of action.
7. Treatment in case of overdose
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
8. Application precautions
Although this drug has not been tested to determine its effect on the ability to drive or operate machinery, it does not appear to have an effect based on its pharmacodynamic properties. It should be taken into account that administration of this drug may cause dizziness when exercising or operating machinery.
9. Other
1) According to preclinical data based on general pharmacology tests, repeated dose toxicity tests, genotoxicity tests, and carcinogenicity tests, there is no special risk to humans. In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
2) According to pharmacokinetic tests, the median AUC and Cmax increased approximately twice in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu
7. Period of use
36 months from date of manufacture
- Active ingredient: Rosuvastatin calcium (EP) ---------- 10.4mg (10mg as rosuvastatin)
- Additives (tar color aluminum lake): Red No. 40, Yellow No. 5
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry pink (03B44038), calcium hydrogen phosphate hydrate, carnaubanap, copovidone, crospovidone
2. Efficacy/Effectiveness
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb): When not controlled through diet and exercise
dietary supplements
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia
4. Pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia who still meet the criteria below despite diet therapy
As an adjunct to diet to reduce total cholesterol, LDL-cholesterol, and apo-B protein levels in patients (for women, at least 1 year after menarche)
◦ If LDL-cholesterol is still greater than 190 mg/dL (LDL-C > 190 mg/dL)
◦ LDL-cholesterol still exceeds 160 mg/dL (LDL-C > 160 mg/dL), family history of premature cardiovascular disease, or two or more cardiovascular diseases
If you have risk factors
5. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
6. Reduced risk of cardiovascular disease: There is no clinical evidence for coronary heart disease, but high-sensitivity C-reactive protein is present in men over 50 years of age and women over 60 years of age.
(high sensitive C-reactive protein, hsCRP) is greater than 2 mg/L, and at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level,
in patients with risk factors such as smoking or a family history of premature coronary heart disease)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Usage/Dosage
1. Primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and
Homozygous familial hypercholesterolemia:
Patients before and while taking this drug should eat a standard cholesterol-lowering diet, and this should be continued during the treatment period. Take this medicine at any time of the day, regardless of meals.
Medication can be administered. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. Maintenance dose: once a day
At 10 milligrams, most patients are controlled at this dose. The maintenance dose is administered at intervals of 4 weeks or more depending on LDL-cholesterol levels, treatment goals, and patient response.
It must be adjusted appropriately, and the dose can be increased up to 20 milligrams per day.
2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age):
The usual dosage range is 5 milligrams to 20 milligrams once daily. (There is no clinical data on doses higher than 20 milligrams administered in the pediatric patient group.) The administered dose varies depending on the individual patient.
Adjust individually according to recommended treatment goals. The dosage should be adjusted at intervals of 4 weeks or more. Safety and efficacy for children under 10 years of age have been established.
There is not.
3. Elderly: No dosage adjustment is necessary.
4. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. 20 mg of this drug for patients with moderate renal failure
Particular care must be taken when administering.
5. Patients with liver failure: In patients with a Child-Pugh score of 7 or less, no increase in systemic exposure of rosuvastatin was observed, but in patients with a Child-Pugh score of 8 or 9, there was no increase in systemic exposure of rosuvastatin.
increased. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. In patients with active liver disease
Do not administer this drug.
6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
7. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. For some of these patients, administration of a 40-milligram dose of this drug may be
It's taboo.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the components of this drug
2) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
3) Patients with myopathy
4) Patients taking cyclosporine concurrently
5) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
6) Pregnant and lactating women, and women of childbearing potential who do not use appropriate contraceptive methods.
This drug should be administered to women of childbearing age only when there is a high possibility that they will not become pregnant and when they have been informed of the potential risk to the fetus.
7) Administration of this drug at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal damage (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Like other HMG-CoA reductase inhibitors, this drug should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting treatment with this drug. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before taking this drug.
2) As with other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as unexplained myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving this drug. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including this drug. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with kidney damage
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
․ During treatment, you should immediately report any unexplained muscle pain, weakness, or cramps, especially if they are associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting this drug or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
․ Because it may make interpretation of the measurement results difficult, do not measure CK after intense exercise or when there are other causes that may increase CK values. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
3) Administration of this drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
4) Statin drugs can rarely cause or worsen severe muscle atony or ocular muscle atony, and cases of recurrence have been reported when the same or different types of statin drugs were administered. This drug should be used with caution in patients with these conditions, and treatment should be discontinued if severe muscle or ocular muscle atony is induced or worsens.
5) In clinical trials, there was no evidence of increased effect on skeletal muscle in the small number of patients who received this drug in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyrosporin, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams is contraindicated when administered concomitantly with fibrate-based drugs.
6) In patients taking high doses, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving 40 mg.
7) Pharmacokinetic tests showed that systemic exposure increased (median AUC and Cmax increased approximately 2-fold) in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
8) Pediatric patients aged 10 - 17 years: In pediatric patients taking rosuvastatin, evaluation of secondary sexual characteristics, linear growth (height), weight, and BMI (body mass index) by Tanner staging is limited to one year.
9) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
*Table: Refer to manual
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered this drug, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) with or without acute renal failure have been reported in patients treated with all doses of this drug (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving this drug. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Eye disorders: Ocular muscle atony (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with eosinophilia and systemic symptoms (DRESS), lichenoid drug rash (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks).
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, adverse drug reactions for which a causal relationship with this drug cannot be ruled out were 2.92% (90 people, 106 cases).
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
7) Pediatric patients aged 10 to 17 years
In a 52-week clinical trial conducted on pediatric patients aged 10 to 17 years, elevated creatinine kinase levels exceeding 10 times the upper limit of normal range (10 x ULN) after exercise and increased physical activity were observed more frequently than in adult patients. In other respects, the safety profile of pediatric patients was similar to that of adults.
4. General precautions
1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including this drug. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
3) An increase in HbA1c and fasting blood sugar levels was reported when administering HMG-CoA reductase inhibitors, including this drug.
4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
5) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
6) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), increased eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
5. Interaction
1) How other drugs affect this drug
In vitro and in vivo studies have shown that this drug does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
This drug is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. If this drug is used together with an inhibitor of this transporter protein, the blood concentration of this drug may increase, increasing the risk of myopathy (see table below).
*Table: Refer to manual
The following drugs did not have a clinically significant effect on the AUC ratio of rosuvastatin when administered in combination with rosuvastatin.
- Aleglitazar 0.3 mg for 7 days; Fenofibrate 67 mg 3 times daily for 7 days; Fluconazole 200mg once daily for 11 days; fosamprenavir 700 mg/ritonavir 100 mg twice daily for 8 days; Ketoconazole 200 mg twice daily for 7 days; Rifampin 450 mg once daily for 7 days; Silymarin 140mg 3 times a day for 5 days
Effects of other drugs
- Antacids: As a result of co-administration of this drug with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by approximately 50%. However, this effect was alleviated when antacids were administered 2 hours after administration of this drug. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
- Ticagrelor: Ticagrelor has been shown to increase rosuvastatin concentrations and may increase the risk of myopathies, including rhabdomyolysis. When coadministered, the benefit of preventing major cardiovascular events associated with rosuvastatin use and the risk of increased rosuvastatin plasma concentrations should be considered. When 90 mg of ticagrelor was administered and 10 mg of rosuvastatin was administered 1 hour later, the Cmax and AUC of rosuvastatin increased by about 2.6 times.
2) How this drug affects other drugs
- Warfarin: When used in combination with this drug, warfarin has no significant effect on pharmacokinetics. However, as with other HMG-CoA reductase inhibitors, co-administration of this drug and warfarin may increase the INR compared to administration of warfarin alone. In patients receiving vitamin K antagonists (e.g. warfarin), INR monitoring is recommended when starting, discontinuing, or adjusting the dose of this drug.
- Cyclosporine: Co-administration of this drug and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMG-CoA reductase inhibitors. When co-administered with fibrate drugs, administration of 40 mg of this drug is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data on patients taking this drug and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
6. Administration to pregnant and lactating women
The safety of this drug in pregnant and lactating women has not been established, so it should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using this medicine, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. Limited data have been reported on the transfer of this drug into breast milk in humans, and there is a potential risk of adverse effects in infants due to its mechanism of action.
7. Treatment in case of overdose
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
8. Application precautions
Although this drug has not been tested to determine its effect on the ability to drive or operate machinery, it does not appear to have an effect based on its pharmacodynamic properties. It should be taken into account that administration of this drug may cause dizziness when exercising or operating machinery.
9. Other
1) According to preclinical data based on general pharmacology tests, repeated dose toxicity tests, genotoxicity tests, and carcinogenicity tests, there is no special risk to humans. In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
2) According to pharmacokinetic tests, the median AUC and Cmax increased approximately twice in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu
7. Period of use
36 months from date of manufacture
Product Updates
Total 6items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 6 | Rotrovan Tab. 10mg | Indications and Precautions for Use | 2024.04.12 | Rosuvastatin calcium single agent (content 5, 10, 20 mg, film-coated tablet) unified adjustment (draft) (efficacy, effect, four weeks)_Change comparison table added.pdfFile under review |
| 5 | Rotrovan Tab. 10mg | Precautions for use | 2023.04.06 | PDF0080_201400154_Precautions for use_Rotroban tablet 10mg (including change comparison table).pdf |
| 4 | Rotrovan Tab. 10mg | Precautions for use | 2022.01.25 | PDFLotroban 10mg change plan (final).pdf |
| 3 | Rotrovan Tab. 10mg | Precautions for use | 2021.08.11 | PDFRosuvastatin calcium single agent (5mg, 10mg, 20mg film coated tablets) unified adjustment (draft) (including change comparison table).pdf |
| 2 | Lotroban tablet 10mg | Lotrovan Tablet 10 mg (Precautions for use) | 2017.01.06 | HWPRosuvastatin calcium single tablet unification adjustment plan.hwp |
| 1 | Lotroban tablet 10mg | Lotrovan Tablet 10 mg (Precautions for use) | 2015.06.26 | HWPRosuvastatin calcium_single tablet_unification adjustment plan.hwp |